Blood Biomarkers Tracked MRI-Confirmed Multiple Sclerosis Activity More Closely Than Symptoms Alone
A commercially available multi-analyte blood assay separated multiple sclerosis relapse biology from pseudoexacerbation with surprising precision in a single-center retrospective cohort. In a disorder where fatigue, heat sensitivity, infection, and other noninflammatory triggers can mimic relapse, the ability to anchor symptoms to objective inflammatory activity has immediate bedside value. The study paired Octave® Multiple Sclerosis Disease Activity testing with MRI before glucocorticosteroid exposure, then asked whether the blood profile could flag the same patients who showed gadolinium-enhancing lesions on imaging.
The answer was yes, and the signal was stronger than neurofilament light alone.
A Smaller Blood Signal Carried More Relapse Information Than NfL Alone
Sixty-six individuals with relapsing-remitting MS were included. Half were assessed for acute neurological symptoms concerning for exacerbation, and the other half were seen for routine disease surveillance. Among symptomatic patients, the blood test preceded MRI in 79% of cases, creating a practical preview of inflammatory activity before imaging was completed. In a clinic where treatment decisions often have to be made before the full diagnostic picture is available, that sequence matters because it mirrors real-world care rather than a controlled trial schedule.
Across both cohorts, a Disease Activity Score between 6.0 and 10.0 was highly sensitive and specific for predicting gadolinium-enhancing lesions. The strongest biological correlate was not a single protein but the broader composite score, which suggests that the inflammatory footprint of MS relapse is better captured by multiple circulating pathways than by a lone marker. The composite outperformed neurofilament light, with an area under the curve of 98.06% versus 82.75% for NfL alone. In practical terms, a broad proteomic pattern recognized MRI-confirmed enhancement more accurately than a marker often treated as a surrogate for axonal injury.
The Biomarker Pattern Fits Active Neuroinflammation
The protein profile associated with gadolinium enhancement looked biologically coherent. Participants with enhancing lesions had elevated myelin oligodendrocyte glycoprotein and neurofilament light, along with reduced B-cell activating factor. Each of those changes points in a different direction within the inflammatory cascade. Elevated NfL reflects neuronal and axonal injury, while myelin oligodendrocyte glycoprotein is consistent with active myelin-related immune activity. Lower B-cell activating factor may reflect altered humoral immune signaling in the setting of acute disease activity.
This combination makes pathophysiologic sense in relapsing MS, where acute symptoms can arise from active demyelination, inflammatory recruitment, and tissue injury occurring at the same time. MRI enhancement captures blood-brain barrier disruption and lesion activity, but the scan is a snapshot. A circulating multi-analyte signature may preserve more of the biology that unfolds over hours to days, which helps explain why the assay aligned so closely with radiographic relapse.
Why the Timing of the Test Matters in Daily MS Practice
The study was designed around a clinically difficult moment: the patient with new weakness, sensory change, imbalance, or visual symptoms who may be relapsing, but may also be experiencing a pseudoexacerbation. Steroid exposure before sampling would have risked blunting the inflammatory signal, so testing was performed before glucocorticosteroid treatment. That detail keeps the result anchored to untreated disease activity rather than treatment response.
In the symptomatic cohort, the blood test often came first. That is not a trivial workflow detail. A test that arrives before MRI can help clinicians decide whether an urgent scan is likely to show inflammatory activity, whether a symptom cluster warrants closer escalation, and whether a patient with ambiguous worsening might be spared overcalling a relapse when the biology is quiet. In MS clinics, where relapse adjudication often drives steroid use, imaging urgency, and treatment adjustment, a reliable blood marker could reduce both delay and uncertainty.
The routine surveillance cohort also matters. Relapse biology is not limited to patients walking into clinic with obvious new symptoms. Ongoing inflammatory activity can simmer below the threshold of a clear clinical event, and a blood assay that identifies enhancement during surveillance could sharpen monitoring between visits, especially in people already receiving or previously exposed to FDA-approved disease-modifying therapy.
What the Data Suggest About Surveillance and Treatment Decisions
The study framed the assay in two settings: acute symptom evaluation and surveillance. In both, the same blood signature tracked with MRI-confirmed activity. That consistency strengthens the case for proteomic testing as more than a convenience tool. It may function as a biologically grounded adjunct to MRI, particularly when access to imaging is delayed or when symptoms are nonspecific.
The finding that the disease activity score outperformed NfL alone also matters clinically. NfL has become an important marker of neuroaxonal injury, but this dataset suggests that a single biomarker may not capture the full inflammatory context of acute MS activity. The composite score appears to integrate multiple layers of disease biology, and the result was a sharper separation between enhancing and non-enhancing disease than NfL provided on its own.
Single-Center Design Leaves Open the Question of Generalizability
The study’s retrospective, single-academic-clinic design limits how far the results can be extended without caution. All 66 participants were drawn from one center, and the cohort was restricted to relapsing-remitting MS. The analysis also focused on paired blood and MRI testing obtained before steroid exposure, which reflects careful selection but does not automatically translate to every outpatient or emergency setting.
The assay was evaluated against MRI enhancement, not against every possible clinical outcome that matters in MS care. Longitudinal relapse prediction, disability accumulation, treatment switching, and performance across broader disease phenotypes were not established here. Even so, the biologic alignment between the blood profile and gadolinium enhancement was strong enough to justify further validation.
A corrected version of the article was later issued, reinforcing the need for careful interpretation of the final dataset. For now, the clearest takeaway is narrow and useful: in a small real-world MS cohort, a multi-analyte blood test identified MRI-confirmed inflammatory activity more accurately than NfL alone, and it did so in a setting that resembles the clinical uncertainty neurologists face every day.